Elite Pharmaceuticals Inc (OTCMKTS:ELTP) reported the issuance of new patent which expands the intellectual property for its ‘opioid abuse deterrent’ technology. The company now has 2 Canadian patents and 4 US patents issued in this area with more patents pending in the Europe, U.S. and Canada.

Nasrat Hakim, the CEO and President expressed that they are delighted with this additional patent as it expands the number of patents that have been issued in the U.S. to Elite which covers its lead abuse deterrent technologies.

The technology

Elite’s abuse resistant technology is a multi-particulate capsule which covers an opioid agonist along with naltrexone, an opioid antagonist. It is utilized mainly in the management of opioid dependence and alcohol dependence. When this product is consumed as said, the naltrexone is set to pass through the human body unabsorbed. At the same time, the opioid agonist is released offering therapeutic pain relief.

If the multi-particulate beads are dissolved or crushed, the naltrexone is set to be released from the developed formulation. The assimilation of the naltrexone is projected to block the euphoria experienced by a potential abuser by binding to the similar receptors in the brain like opioid agonist. As a result, it minimizes the incentive for misuse or abuse by recreational drug addicts. Elite’s pharmacological practice to abuse-deterrence can be used in a wide range of opioids advised in pain management.

The performance

Elite Pharmaceuticals Inc (OTCMKTS:ELTP) announced that consolidated revenues for FY2015 surged 9% to cross $5 million for the first time in company’s history. The sharp jump in revenue was possible due to the expansion of company’s generic product lines.

In last trading session, the stock price of ELTP declined more than 1% to close the trading session at $0.219. The decline came at a share volume of 856,620 compared to average share volume of 1.20 million.

Previous articleGreen Technology Solutions Inc (OTCMKTS:GTSO) Revising Market Strategy
Next articleWhy Is Lifelogger Technologies Corp (OTCMKTS:LOGG) Declining Consistently?
Steve Kanaval: Portfolio Manager/Writer/ Market Analyst Steve began his career in the Trading Pits in Chicago making markets at the Chicago Mercantile Exchange (NYSE:CME) the Chicago Board of Trade and the CBOE in the early 80’s. He ran the Morgan Stanley Derivative Prop Trading for the firm specializing in Index Arbitrage. He continued his career as a Trader/Portfolio Manager for multiple Hedge Funds during the Internet Boom of the 90’s managing large portfolios. Steve is known as an expert in MicroCap Technology Stocks and the emerging Digital Currency markets as a Portfolio Manager for his Family Office. Steve has managed portfolio’s in volatile asset classes for 3 decades as a commodity trader, hedge fund manager and digital currency trader and miner. Steve publishes his views on the asset classes in a public forum and has published more than 10,000 articles simplifying these complex and volatile assets for readers. His work is published on multiple sites including Bloomberg,,, CryptoCurrencyNews as a paid contributor. His work includes research, journalism and archived video on important market volatility related to stocks, digital currency and other volatile misunderstood asset classes. He offers a humorous, unique insight and the related back stories and drivers for readers interested in volatility and emerging market assets. Full disclosure Steve is long 25 digital currencies and sits on the board of multiple public companies involved in digital currencies, and owns shares in these companies from time to time.